Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie med ctDNA-testning för att informera standardvårdsbehandlingsbeslut hos personer med endometriecancer

24 september 2026 uppdaterad av: Memorial Sloan Kettering Cancer Center

Pragmatisk pilotstudie av ctDNA-informerad deeskalering av immuncheckpoint-hämmare vid avancerad/återkommande mismatch-reparationsbrist (MMR-D)/mikrosatellitinstabilitet hög (MSI-H) endometriecancer med standardbehandlingar

The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair deficient (MMR-D) gene or microsatellite instability high (MSI-H) gene. The researchers will see how doctors and their patients use the results of ctDNA testing after 1 year of standard chemotherapy and immune checkpoint inhibitor (ICI) treatment to decide whether to continue maintenance ICI treatment past 1 year. The researchers will also look at the health outcomes of people in this study (for example, whether they are cancer free at the end of their participation in the study).

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

30

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Ying Liu, MD, MPH
  • Telefonnummer: 646-888-4946
  • E-post: liuy6@mskcc.org

Studera Kontakt Backup

  • Namn: Paul Johannet, MD
  • Telefonnummer: 646-888-5327

Studieorter

    • New Jersey
      • Basking Ridge, New Jersey, Förenta staterna, 07920
        • Rekrytering
        • Memorial Sloan Kettering Basking Ridge (All Protocol Activites)
        • Kontakt:
          • Ying Liu, MD
          • Telefonnummer: 646-888-4946
      • Middletown, New Jersey, Förenta staterna, 07748
        • Rekrytering
        • Memorial Sloan Kettering Monmouth (All Protocol Activities)
        • Kontakt:
          • Ying Liu, MD
          • Telefonnummer: 646-888-4946
      • Montvale, New Jersey, Förenta staterna, 07645
        • Rekrytering
        • Memorial Sloan Kettering Bergen (All Protocol Activities)
        • Kontakt:
          • Ying Liu, MD
          • Telefonnummer: 646-888-4946
    • New York
      • Commack, New York, Förenta staterna, 11725
        • Rekrytering
        • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
        • Kontakt:
          • Ying Liu, MD
          • Telefonnummer: 646-888-4946
      • Harrison, New York, Förenta staterna, 10604
        • Rekrytering
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
        • Kontakt:
          • Ying Lui, MD
          • Telefonnummer: 646-888-4946
      • New York, New York, Förenta staterna, 10065
        • Rekrytering
        • Memorial Sloan Kettering Cancer Center
        • Kontakt:
          • Roisin O'Cearbhaill, MD
          • Telefonnummer: 646-888-4227
        • Kontakt:
          • Ying Liu, MD, MPH.
          • Telefonnummer: 646-888-4946
      • Rockville Centre, New York, Förenta staterna, 11570
        • Rekrytering
        • Memorial Sloan Kettering Nassau (All Protocol Activities)
        • Kontakt:
          • Ying Liu, MD
          • Telefonnummer: 646-888-4946

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Patients must have pathologically confirmed endometrial cancer

  • Patients with advanced endometrial cancer

  • Stage III with residual disease

    °Select patients with Stage III disease and no residual disease can be enrolled after discussion with PI

  • Stage IV

  • Recurrent endometrial cancer after adjuvant therapy only

  • Patients can have primary or planned interval surgery

  • MMR-D on immunohistochemistry OR MSI-H using any commercially available test

  • Patients with treated brain metastases are eligible if follow up brain imaging after CNS directed therapy shows no evidence of progression.

  • Eligible for standard of care chemotherapy with immune checkpoint inhibitor per treating investigator with no clinical contraindications

  • For the up to 10 patients who are allowed to enroll after C1D1 of standard of care treatments, they need to be on treatment with no clinical evidence of disease progression.

    • Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy.

    • Patients may have received prior hormonal therapy for treatment of endometrial cancer.

    • Patients may not have received prior therapy with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.

      • Except for the up to 10 patients who are allowed to enroll after C1D1 of standard of care treatments (chemotherapy and/or immune checkpoint inhibitors) per protocol.
  • Age ≥ 18

  • Not Pregnant and Not Nursing

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: ctDNA-negative group

Participants in this group will have negative ctDNA test results at 1 year after they start standard treatment. (Negative results indicate that no cancer DNA is detected in their blood.) Participants in this group will decide with their doctor if they want to stop standard maintenance ICI treatment.

Patients will undergo ctDNA sampling at the 1-year timepoint using the commercially available Natera SignateraTM test.

at the 1-year timepoint

Patients and providers will also complete surveys at various timepoints to evaluate distress, shared decision-making, acceptability and other factors contributing to the decision-making process.

Will be performed within 6 months of receiving the 1-year clinical ctDNA result. Discussion via telephone or during a standard of care clinical visit (in person or telemedicine) with treating physician or team member within 28 days of clinical 1-year ctDNA result to discuss results with the patient and decide on de-escalation if applicable.

Experimentell: ctDNA-positive group

Participants in this group will have positive ctDNA test results at 1 year after they start standard treatment. (Positive results indicate that cancer DNA is detected in their blood.) Participants in this group will continue receiving standard treatment with their doctor.

Patients will undergo ctDNA sampling at the 1-year timepoint using the commercially available Natera SignateraTM test.

at the 1-year timepoint

Patients and providers will also complete surveys at various timepoints to evaluate distress, shared decision-making, acceptability and other factors contributing to the decision-making process.

Will be performed within 6 months of receiving the 1-year clinical ctDNA result. Discussion via telephone or during a standard of care clinical visit (in person or telemedicine) with treating physician or team member within 28 days of clinical 1-year ctDNA result to discuss results with the patient and decide on de-escalation if applicable.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
will test the feasibility of ct-DNA
Tidsram: 1 year

informed de-escalation of standard of care ICI maintenance therapy defined as willingness of patients/providers to stop ICI therapy after 1 year in those with negative ctDNA testing.

1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Ying Liu, MD, MPH, Memorial Sloan Kettering Cancer Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

25 november 2025

Primärt slutförande (Beräknad)

1 november 2027

Avslutad studie (Beräknad)

1 november 2027

Studieregistreringsdatum

Först inskickad

26 november 2025

Först inskickad som uppfyllde QC-kriterierna

26 november 2025

Första postat (Faktisk)

8 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

25 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera